Skip to main content

23-02-2022 | ASCO GU 2022 | Conference coverage | Video

First-line avelumab investigated in cisplatin-unfit advanced UC patients

share
SHARE

Roberto Iacovelli presents the ARIES trial of frontline avelumab in patients with PD-L1-positive advanced urothelial cancer who are unable to tolerate cisplatin (4:19).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany